G protein-coupled protease-activated receptors (PARs) provide one answer to the question of how coagulation factors and other proteases regulate cellular behaviors. In concert with the coagulation cascade, these receptors provide an elegant mechanism that links mechanical information in the form of tissue injury or vascular leak to cellular responses. Roles for PARs in hemostasis and thrombosis, inflammation, and perhaps even blood vessel development are beginning to emerge. Our current understanding of the role of PARs in platelet and endothelial cell activation and their potential importance in normal and disease states is discussed.
Introduction
The serine protease thrombin regulates platelet aggregation, endothelial cell activation, and other important biological responses. Thrombin's actions on cells present an intriguing basic question. How does thrombin, a protease, elicit cellular responses like a traditional hormone? In addition, understanding thrombin signaling promises to provide insight into hemostasis and inflammation, and, probably, embryonic development. Because thrombin and platelets play a central role in arterial thrombosis underlying myocardial infarction and other disease processes, understanding how thrombin activates platelets and other cells may suggest new strategies for therapeutic development.
Protease-activated receptors (PARs) provide one answer to the question of how thrombin signals. PARs are G protein-coupled receptors that utilize an intriguing mechanism to convert an extracellular proteolytic cleavage event into a transmembrane signal. As detailed below, these receptors carry their own ligands, which remain silent until activated by receptor cleavage.
This review will focus on PAR activation by thrombin and the roles of this system in vivo. Recent advances in our understanding of PARs provide a working model for thrombin signaling in human platelets and evoke hypotheses regarding the roles of PARs in thrombosis and inflammation that can be tested in principle with knockout mouse models. It is important to point out that PARs can mediate signaling to proteases other than thrombin and likely serve signaling functions in contexts outside of tissue injury. These issues will be touched upon briefly.
Because PARs were discovered in the context of an effort to understand thrombin signaling, it is useful to consider when and where thrombin is generated as well as its known actions on cells.
Thrombin Generation
Thrombin is the main effector protease of the coagulation cascade, a series of zymogen conversions triggered when circulating coagulation factors contact tissue factor. Tissue factor, a type-I integral membrane protein, is an obligate cofactor for activation of zymogen factor X by factor VIIa. Factor Xa (with the assistance of factor Va as cofactor) then converts zymogen prothrombin to active thrombin. Other zymogen conversions provide both amplification and negative feedback loops that regulate thrombin production. Importantly, thrombin is short-lived in the circulation and, in the context of a normal endothelium, acts to terminate its own production. Thus thrombin is thought to act near the site of its production (1, 2) .
Epithelial cells, macrophages, and other cell types that are normally segregated from blood constitutively express tissue factor. Classically, disruption of vascular integrity allows plasma coagulation factors to contact extravascular tissue factor, thereby triggering thrombin generation. Circulating monocytes and vascular endothelial cells (3) -cells that are normally bathed in coagulation factors -can be induced to express low levels of tissue factor by cytokines and other stimuli. Activated platelets and endothelial cells can tether tissue factor-bearing monocytes and leukocyte-derived microparticles, thereby concentrating tissue factor and activating the coagulation cascade (4, 5) . Like the classical paradigm above, this scenario links tissue injury or inflammation to activation of coagulation proteases. Taken together, these considerations cast thrombin as a local mediator of responses to vascular injury or inflammation and suggest that PAR activation by thrombin might function in this context.
Thrombin's Actions on Cells
Thrombin has a host of direct actions on cells (6) (Fig. 1) . It is perhaps the most effective activator of platelets ex vivo (7) . Thrombin provokes platelet shape change and release of the contents of platelet granules, which contain the platelet ADP and serotonin as well as chemokines and growth factors (8) . Thrombin also triggers synthesis and release of thromboxane A2 (9), mobilization of P-selectin and CD40 ligand to the platelet surface (10, 11) and activation of the integrin ␣ IIb /␤ 3 (12) . The latter binds fibrinogen and vWF to mediate platelet aggregation (1) . Thrombin causes expression of procoagulant activity on the platelet surface, which supports additional thrombin generation (13) . In cultured endothelial cells, thrombin causes release of vWF (14) , display of P-selectin on the plasma membrane (14) , and production of chemokines: actions thought to trigger binding of platelets and leukocytes to the endothelial surface in vivo (15, 16) . Endo-thelial cells change shape and endothelial monolayers show increased permeability in response to thrombin (17) : actions predicted to promote local transudation of plasma proteins and edema (18) . Thrombin can also regulate blood vessel diameter by endothelial-dependent vasodilatation; in the absence of endothelium, thrombin's action on smooth muscle cells evokes vasoconstriction. In fibroblast and vascular smooth muscle cell cultures, thrombin regulates cytokine production and is mitogenic, and thrombin triggers calcium signaling and other responses in T lymphocytes. Especially when taken in the context of thrombin's generation at sites of vascular injury, these cellular actions suggest that thrombin signaling connects tissue damage to both hemostatic and inflammatory responses. They also raise the possibility that regulation of endothelial cells and other cell types by thrombin might play a role in contexts other than tissue injury, for example, in leukocyte transmigration, vascular remodeling, and/or angiogenesis. The recent characterization of receptors that mediate thrombin signaling provides an opportunity to test these ideas.
How Does Thrombin Talk to Cells?
Thrombin signaling is mediated at least in part by a small family of G protein-coupled protease-activated receptors (PARs) (19) . PAR1, the prototype for this family, is activated when thrombin cleaves its Nterminal exodomain at a specific site (20, 21) . This cleavage event unmasks a new N-terminus that then serves as a tethered ligand, binding intramolecularly to the body of the receptor to effect transmembrane signaling (20) (Fig. 2) . Intermolecular ligation of PARs can occur but, not surprisingly, appears to be less efficient than intramolecular ligation (22, 23) . Synthetic peptides that mimic the PAR1 tethered ligand activate the receptor independent of protease and receptor cleavage (20) . Thus PAR1 can be viewed as a peptide receptor that carries its own ligand. The latter remains silent until activated by cleavage of the PAR1 N-terminal exodomain. PAR1-thrombin interactions are accounted for by the sequences surrounding the thrombin cleavage Fig. 1 Thrombin's cellular actions in the context of a blood vessel. Thrombin is a multifunctional serine protease generated at sites of vascular injury. It is arguably the most effective agonist for platelet activation. Thrombin also elicits a host of responses in the vascular endothelium, including shape and permeability changes, mobilization of adhesive molecules to the endothelial surface and stimulation of autocoid and cytokine production. Thrombin is chemotactic for monocytes and mitogenic for lymphocytes and mesenchymal cells. These actions of thrombin may help orchestrate hemostatic and inflammatory responses to tissue injury. Possible roles in blood vessel development are also envisaged Fig. 2 Mechanism of PAR1 activation. Thrombin (large green sphere) recognizes the amino terminal exodomain of the G proteincoupled thrombin receptor PAR1. This interaction utilizes sites both amino (P1-P4, small blue sphere) and carboxyl terminal (P9'-P14'; small pink oval) to the thrombin cleavage site. The latter sequence resembles the carboxyl tail of the thrombin inhibitor hirudin and binds to thrombin in an analogous manner (80) (81) (82) . Thrombin cleaves the peptide bond between receptor residues Arg41 and Ser42. This serves to unmask a new amino terminus beginning with the sequence SFLLRN (diamond) that functions as a tethered ligand, docking intramolecularly with the body of the receptor to effect transmembrane signaling. Synthetic SFLLRN peptide, which mimics the tethered ligand sequence, will function as an agonist independent of receptor cleavage. Thus PAR1 is, in essence, a peptide receptor that carries its own ligand, the latter being active only after receptor cleavage (20) site within PAR1's N-terminal exodomain, and cleavage at that site is both necessary and sufficient for PAR1 activation. Indeed, PAR1 mutants bearing enteropeptidase or trypsin cleavage sites in place of the thrombin cleavage site conferred enteropeptidase or trypsin signaling, respectively, in heterologous expression systems. Thus the role of thrombin in PAR1 activation appears to be simply to unmask the receptor's tethered ligand (6, 19) .
PAR1 can couple to members of the G12/13, Gq, and Gi/z families and hence to a host of intracellular signaling pathways (Fig. 3) . Such pluripotent signaling fits well with the known effects of thrombin on platelets, endothelial, and other cells. For example, in mouse platelets, Gq is necessary for platelet secretion and aggregation in response to thrombin but is not necessary for thrombin-triggered shape change (24) . Shape change is likely mediated by G12/13 (25) . Gz, a Gi family member, is critical for epinephrine's ability to both inhibit cAMP formation and increase the sensitivity of mouse platelets to activation by other agonists (26) . Thus PAR1 coupling to Gz might play an epinephrine-like role in human platelets.
Irreversible Activation and Disposable Receptors
The unusual mechanism by which PAR1 is activated raises important questions. Cleavage of the receptor is irreversible, and the "peptide agonist" unmasked by cleavage remains tethered to the receptor. Given the irreversibility of the activation mechanism, how is PAR1 signaling terminated? Thrombin is an enzyme, implying that one thrombin molecule might cleave and activate several molecules of PAR1. How then does PAR1 mediate responses that are dependent upon thrombin concentration? And, given tethering of ligand to receptor, will it be possible to develop drugs that block PAR1 signaling? There are hints of interesting answers (19) . (83) (84) (85) to impact a substantial network of signaling pathways. The ␣ subunits of G12 and 13 bind RhoGEFs (guanine nucleotide exchange factors, which activate small G proteins) (86) (87) (88) , providing a path to Rho-dependent cytoskeletal responses that are likely involved in shape change in platelets (25) and permeability and migration in endothelial cells (89, 90) . G␣q activates phospholipase C␤ thereby triggering phosphoinositide hydrolysis, calcium mobilization and protein kinase C activation (91) . This provides a path to calcium-regulated kinases and phosphatases, GEFs, and MAP kinase cassettes and other proteins that mediate cellular responses ranging from granule secretion, integrin activation, and aggregation in platelets (24) to transcriptional responses in endothelial and mesenchymal cells. G␣i inhibits adenylyl cyclase, an action known to promote platelet responses. G␤␥ subunits can activate phosphoinositide-3 kinase (92) and other lipid modifying enzymes, protein kinases, and channels (93) . Phosphoinositide-3 kinase modifies the inner leaflet of the plasma membrane to provide attachment sites for a host of signaling proteins (94) . PAR1 activation can also activate cell surface "sheddases" that liberate ligands for receptor tyrosine kinases, providing a link between thrombin and receptors involved in cell growth and differentiation (95) . The pleiotrophic effects of PAR1 activation are consistent with many of thrombin's diverse actions on cells Like other G protein-coupled receptors, activated PAR1 is rapidly uncoupled from signaling and internalized by phosphorylation-dependent mechanisms (27) (28) (29) . Instead of recycling, it is then delivered to lysosomes with remarkable efficiency and degraded (28, (30) (31) (32) . Some PAR1 molecules that escape this fate appear to return to the cell surface with the tethered ligand in an inactive state (33, 34) . Thus PAR1 is used once and then discarded. In fibroblasts and endothelial cells, responsiveness to thrombin is maintained by delivery of naive PAR1 to the cell surface from a preformed intracellular pool (30) . By contrast, in human megakaryocyte-like cell lines, recovery of PAR1 signaling requires new protein synthesis (28, 30) . Perhaps there is no need for a special resensitization mechanism in platelets. Once activated and incorporated into a clot, they are presumably not reused.
The rapid shut off of activated PAR1 provides a plausible answer to how PAR1 mediates responses that are proportional to thrombin concentration (33) . Each cleaved receptor is active for only a finite interval and therefore should elicit production of some average "unit" of second messenger (e. g., inositol trisphosphate) before shutting off. Because the second messenger is itself cleared, the level of second messenger achieved should be proportional to the rate at which receptors are cleaved and activated and hence to thrombin concentration.
Can an effective PAR1 inhibitor be developed? Antagonists that compete with the tethered ligand will likely need high affinity for PAR1 to effectively block its activation. Antagonists structurally related to the PAR1 tethered ligand have been generated (35, 36) but whether these can be made sufficiently potent to be useful in vivo is unclear. In principle, noncompetitive antagonists may provide an alternative, and the platelet ADP receptor blockers ticlopidine and clopidogrel provide an interesting precedent in this regard (37, 38) . Lastly, because each activated PAR1 is rapidly shutoff and because platelets must presumably respond rapidly to contribute to a thrombus, it is conceivable that merely slowing thrombin receptor activation on platelets might have a useful therapeutic effect. Clearly more work is needed.
A Family of PARs
Four PARs are known. Human PAR1 (20, 21) , PAR3 (39) , and PAR4 (40, 41) can be activated by thrombin. PAR2 can be activated by trypsin (42) and tryptase (43) as well as by coagulation factors VIIa and Xa (44, 45) but not by thrombin. These receptors have a basic residue at P1 in the activating cleavage site, and in principle, any protease capable of cleaving these sites can trigger PAR signaling. Thus it is certainly possible that these receptors mediate responses to other proteases in vivo. Moreover, cofactors that localize proteases to the cell surface and modulate their activity can help orchestrate PAR activation (45, 46) . Thus the full repertoire of proteases that signal through PARs remains to be defined.
It is worth noting that the N-terminal exodomains of PAR1 and PAR3 have thrombin-interacting sequences both N-and C-terminal to the thrombin cleavage site (Fig. 2) . The C-terminal sequence resembles the carboxyl tail of the leech anticoagulant hirudin and, like the latter, binds to thrombin's fibrinogen-binding exosite; this interaction is important for receptor cleavage at low concentrations of thrombin (6) . The presence of such extended thrombin interacting sequences in PAR1 and PAR3 is consistent with the notion that these receptors evolved to mediate responses to thrombin vs. other proteases. A hirudin-like sequence is not evident in PAR4, and PAR4 indeed requires higher thrombin concentrations for activation than the other receptors (40, 41) .
PARs and Platelet Activation
Recent studies provide a working model of thrombin signaling in human and mouse platelets and reveal both curious species differences and a variation on the paradigm for PAR activation. The model frames important questions regarding strategies for drug development and suggests that answers, at least in principle, can be derived from studies of PAR knockout mice (Fig. 4) . Fig. 4 Thrombin receptors in human and mouse platelets. Human platelets express PAR1 and PAR4, and available data suggest that these receptors can independently mediate thrombin signaling: PAR1 at low thrombin concentrations and PAR4 at high thrombin concentrations. By contrast, mouse platelets express PAR3 and PAR4, and, surprisingly, it appears that mPAR3, rather than itself mediating transmembrane signaling, functions as a cofactor that supports cleavage and activation of mPAR4 at low thrombin concentrations. These species differences are fortunate in that they provide an opportunity to address key questions regarding the PAR signaling in a convenient way in mouse models (see text)
Thrombin Receptors in Human Platelets
Human platelets express PAR1 and PAR4, and activation of either is sufficient to trigger platelet secretion and aggregation (20, 40, 47) . Antibodies to the thrombin interaction site in PAR1 blocked platelet activation at low but not high concentrations of thrombin (47) (48) (49) . Similar results were obtained with a PAR1 antagonist (35, 47) . By contrast, PAR4-blocking antibodies by themselves had no effect on platelet activation by thrombin, but when these were combined with PAR1 blockade, platelet activation was markedly inhibited even at high concentrations of thrombin (47) . These results suggest that PAR1 mediates activation of human platelets at low thrombin concentrations and that, in the absence of PAR1 function, PAR4 can mediate platelet activation but only at high thrombin concentrations (Fig. 4) .
If PAR1 is sufficient to mediate platelet activation at low concentrations of thrombin, what does PAR4 contribute? It is possible that PAR4 simply provides some redundancy in an important system or that PAR1 and PAR4 interact. It is equally possible that PAR4, which lacks a thrombin-binding hirudin-like sequence, contributes responsiveness to proteases other than thrombin. In this regard, platelet activation by cathepsin G (50), a granzyme released by activated neutrophils, appears to be mediated by PAR4 (51) . PAR4 may make other unique contributions to platelet function. Indeed, PAR4 is activated and shutoff more slowly than PAR1, and the tempo of calcium signaling to thrombin in human platelets appears to represent the sum of contributions of both receptors (52, 53) . Differences in G protein coupling also exist between PAR1 and PAR4 (at least for the human isoforms). Like hPAR1, hPAR4 activates Gq and probably G12/13 signaling, but unlike hPAR1, hPAR4 does not appear to couple to Gi (40, 47, 54, 55) . The importance of this difference for platelet function is unknown.
In addition to interacting with PARs, thrombin also binds to glycoprotein Ib␣ (GPIb␣) on the surface of human platelets (56) . GPIb␣ is part of a multifunctional protein complex that also binds vWF and P-selectin (57) . Platelets from patients with Bernard-Soulier syndrome lack surface GPIb␣ and show decreased thrombin responsiveness, but such platelets are also structurally abnormal (58-61). However, antibodies that block thrombin binding to GPIb␣ attenuate platelet activation by thrombin and decrease PAR1 cleavage (60, 62, 63) . These and other observations support the model that GPIb␣ may serve as a cofactor for thrombin cleavage of PARs on the platelet surface, analogous to the interaction between PAR3 and PAR4 described in mouse platelets (46) . Attempts to directly demonstrate such activity by coexpressing the GPIb complex with PARs have been unsuccessful (46) , but the significance of such negative results is unclear. Clearly more work is needed on this question. Recently, Ware and colleagues reported a GPIb␣ knockout mouse that recapitulated many features of human Bernard-Soulier syndrome; a human GPIb␣ transgene rescued the Bernard-Soulier phenotype (64) . Although species differences come into play (see below), similar use of GPIb␣ transgenes with specific mutations might allow a direct assessment of the role of GPIb␣'s thrombin binding activity in mouse platelet function.
The presence of PAR1 and PAR4 in human platelets raises an important question regarding the development of antithrombotic drugs. Given that activation of PAR4 requires relatively high concentrations of thrombin, might inhibition of PAR1 be sufficient to prevent thrombosis? Or will inhibition of both PAR1 and PAR4 be required? In the absence of specific antagonists that might be used to address this question in relevant animal models, near term answers will likely come from the study of PAR-deficient mice.
Thrombin Receptors in Mouse Platelets
In contrast to human platelets, mouse platelets express PAR3 and PAR4 (41) . Indeed, PAR1-activating peptides activate human but not murine platelets (65) (66) (67) , and such peptides are fully active on mouse PAR1 in heterologous expression systems (67) . Moreover, knockout of mPAR1 had no effect on thrombin signaling in mouse platelets but ablated thrombin signaling in fibroblasts (67) . These observations triggered a search for other thrombin receptors in mouse platelets and led to identification of PAR3 (39) . Expression of human PAR3 cDNA in COS cells or Xenopus oocytes conferred phosphoinositide hydrolysis in response to low concentrations of thrombin, and in situ hybridization using a mouse PAR3 probe detected mPAR3 mRNA in mouse megakaryocytes (39) . Thus mouse PAR3 appeared to be a good candidate for the "missing" mouse platelet thrombin receptor, and indeed, knockout of mouse PAR3 revealed it to be necessary for activation of mouse platelets at low but not high concentrations of thrombin (41) . Signaling in response to high concentrations of thrombin in PAR3-deficient mouse platelets was attributable to mPAR4 (41) . At face value, these data conjured a dual receptor model analogous to that described above for human platelets. In mouse platelets, PAR3 mediated activation at low thrombin concentrations and, in the absence of PAR3 function, PAR4 triggered activation at high thrombin concentrations (41) .
Subsequent characterization of the mouse homologue of PAR3 presented a paradox. Despite strong evidence that mPAR3 was necessary for mouse platelet responses to low concentrations of thrombin, expression of mPAR3 cDNA in heterologous expression systems failed to confer thrombin signaling. Nontrivial explanations for this paradox include the idea the platelets express a molecule required for mPAR3 function that was not present in the heterologous expression systems examined. Resolution of this paradox came in the form of an interesting variation on the mechanism of PAR activation (46) . While expression of mPAR3 in COS cells did not by itself confer thrombin signaling, co-expression of mPAR3 with mPAR4 reliably enhanced both mPAR4 cleavage and signaling at low concentrations of thrombin compared to that seen with mPAR4 alone. When tethered to the plasma membrane, the N-terminal exodomain of mPAR3 was sufficient for this activity, and the thrombin-interacting sequences within this domain were necessary. Thus it appears that mPAR3 does not by itself mediate transmembrane signaling but instead functions as a cofactor for cleavage and activation of mPAR4 at low thrombin concentrations. This represents a curious form of G protein-coupled receptor interaction in which one receptor acts as an accessory protein that aids "ligation" of another (Fig. 3) (46) . This model predicts that thrombin signaling in mouse platelets is PAR4-dependent. A definitive test of this prediction will be possible with platelets from PAR4-deficient mice, which should be unresponsive to thrombin despite the presence of mPAR3 (Fig. 3) . Whether mPAR3 and mPAR4 heterodimerize and whether other similar PAR-PAR interactions will be found is unknown.
Perhaps surprisingly, no evidence was found to suggest a similar cofactor relationship between hPAR1 and hPAR4 or between GPIb␣ and hPAR1 or hPAR4 when these molecules were co-expressed in same systems in which the mPAR3-mPAR4 interaction was detected (46) . It is certainly possible that such negative results were due to differences in absolute or relative expression levels achieved in these systems vs. platelets or to other technical issues, but it is also possible that there is something special about the interaction between mPAR3 and mPAR4.
Potential Role of Platelet PARs in Thrombosis
Parallels between human and mouse systems and utility of mouse models. Thrombosis of the arteries that supply the heart, brain, and other vital organs is a major cause of morbidity and mortality. Both thrombin and platelets are clearly important in acute arterial thrombosis and, given the remarkable effectiveness of thrombin as a platelet agonist, it is reasonable to postulate an important role for platelet activation by thrombin. However, thrombin has many actions and platelets respond to multiple agonists. The relative importance of thrombin signaling in platelets in the complex interplay among platelet, plasma and vessel wall factors in thrombosis is unknown. Despite species differences, mouse models may provide important hints regarding the importance of thrombin signaling in platelets and whether inhibition of thrombin signaling in human platelets might be useful as an antithrombotic strategy. The model in Fig. 4 makes several predictions. First, PAR3-deficient mouse platelets are analogous to PAR1-inhibited human platelets. Functionally, both have decreased but not absent thrombin responses, and, mechanistically, both rely on PAR4 for thrombin signaling. If PAR3-deficiency protects against thrombosis in mouse models, PAR1 inhibition may be worth investigating as a possible antithrombotic strategy in man. Second, PAR4-deficient mouse platelets may be analogous to human platelets in which both PAR1 and PAR4 function are blocked -thrombin signaling should be absent in both. Thus a PAR4-deficient mouse may provide an opportunity to define the importance of thrombin-triggered platelet activation in hemostasis and thrombosis. As noted above, given the multiple actions of thrombin and the many routes to platelet activation, the phenotype of a mouse with absent thrombin signaling in platelets would be informative indeed.
PARs in Endothelial Activation
PAR1 appears to be the major mediator of thrombin signaling in vascular endothelial cells in both mouse and man, and most of the actions of thrombin on endothelial cells cited above have been reproduced using PAR1 agonist peptide. Endothelial cells also express PAR2, which may mediate responses to mast cell-released tryptase (43) or to coagulation factors VIIa or Xa (45) in this setting.
What functions do endothelial PARs serve? One might imagine the following scenario. Tissue injury, whether by trauma, infection, or metabolic or inflammatory mediators, triggers local generation of coagulation proteases and/or release of mast cell tryptase, which, via PARs, activate endothelial cells (Fig. 1) . The activated endothelial sur- (68, (96) (97) (98) . This leads to adhesion, rolling, and eventually attachment and activation of platelets and leukocytes at the endothelial surface. Local concentration of tissue factor-bearing leukocytes and microparticles (4, 5) and platelet procoagulant activity (13) may promote further thrombin generation (99) . Thrombin also increases endothelial permeability, and PAR activation triggers edema formation at least in part by triggering mast cell degranulation (18) . This too may promote additional thrombin generation as plasma coagulation factors contact extravascular tissue factor. Platelets and leukocytes can directly activate endothelial cells by presenting CD40L and other mediators, thereby upregulating not only adhesion molecules and cytokines (11) but also tissue factor and PAR2 (3, 100) . Leukocytes and platelets can themselves interact via P-selectin (99) , and neutrophils can activate platelets by release of the granzyme cathepsin G. Ultimately, leukocyte products may directly injure tissues, and thrombin may trigger fibrin formation, platelet aggregation, microvascular thrombosis. Localized, such a system may be useful for isolating and destroying pathogens. Undamped positive feedback between coagulation and inflammation is made more likely by cellular responses to endotoxin (101) and by genetic deficiencies in natural anticoagulant pathways (102) and is associated with hemorrhagic infarction of tissues. Clearly a host of cell types and signaling systems orchestrate inflammatory responses, and the relative importance of PARs in sepsis and in less dramatic inflammatory processes remains to be tested face in turn promotes adhesion and rolling of platelets and leukocytes as well as access of plasma proteins to the extravascular space. Thrombin also triggers endothelial production of platelet-activating factor, a potent platelet and leukocyte activator (68) , as well as IL-6 and IL-8 (69) . Thus PARs may link tissue injury to endothelial responses that recruit platelets, leukocytes, and effector proteins to examine the locale for damage or infection.
The possibility of a positive feedback loop in which thrombin triggers endothelial responses that beget additional thrombin generation and endothelial activation is apparent (Fig. 5) . On a microscopic scale, this might be beneficial for walling off infection. However, disseminated intravascular coagulation with microvascular thrombosis and tissue infarction can occur in the setting of a strong systemic inflammatory stimulus (e.g., sepsis) and/or deficiencies that disinhibit thrombin production (e. g., protein C deficiency, protein S deficiency and factor V Leiden; see figure) .
PAR-deficient mice provide an opportunity to test the role of endothelial PARs in inflammatory responses. The species differences in PAR expression between mouse and human may be fortunate in this regard. PAR1 appears to be the major thrombin receptor in endothelial cells in both species. However, because PAR1 is expressed in human but not mouse platelets, PAR1-deficient mice may offer an opportunity to ablate thrombin signaling in endothelial cells without perturbing platelet signaling, thereby defining the contribution of endothelial activation by thrombin in models of thrombosis and inflammation. Intriguingly, PAR1-deficiency did protect against leukocyte infiltration and renal damage in a mouse model of antibody-mediated glomerulonephritis (70) and PAR2-deficiency decreased leukocyte rolling in exteriorized cremasteric preparations (71) .
Thrombin Signaling in Embryonic Development
Strikingly, approximately half of PAR1-deficient embryos die at midgestation (67) . PAR1 does not function in mouse platelets (see above). Moreover, platelets are not required for normal development through midgestation (72) . Thus it is difficult to ascribe death of PAR1-deficient embryos to a platelet function defect. Knockout of several coagulation factors also causes variable degrees of embryonic loss at midgestation, in some cases associated with abnormal vascular development (73) (74) (75) (76) (77) . These and other recent studies (78) suggest that signaling by coagulation proteases and PARs may play an important role in embryonic development that is unrelated to hemostasis in any usual sense, perhaps by contributing to normal blood vessel development. This is exciting in that it may point to a new role for the "coagulation" cascade -one of monitoring and regulating new blood vessel formation. A detailed review of this rapidly evolving area is beyond the scope of this article.
Future Directions
The studies cited above raise a host of questions regarding the molecular mechanisms of PAR activation and protease signaling. How general are PAR-PAR interactions and is oligomerization involved? To what extent do cofactors increase the diversity of proteases to which cells can respond via PARs? Will known PARs account for signaling by thrombin and other coagulation proteases or will new PARs and/or other paradigms be identified? Because PAR1 and PAR4 are the only PARs known to mediate transmembrane signaling in response to thrombin in the mouse, the presence or absence of residual thrombin signaling in cells from mice deficient in both PAR1 and PAR4 will be telling.
Important questions also remain regarding the roles of PARs in physiology and disease. It is clear that both thrombin and platelets are important for hemostasis and thrombosis. However, in addition to activating platelets, thrombin triggers fibrin formation and a host of other cellular events, and platelets can be activated by a host of mechanisms. Thus the relative importance of thrombin activation of platelets in hemostasis and thrombosis is unknown. As discussed above, the phenotype of PAR4 knockout mouse may be enlightening. Similarly, a panoply of signaling systems and cell types orchestrates inflammatory responses, and efforts to define the relative contribution of PARs in endothelial cells and leukocytes are just beginning.
The answers to the questions posed above will influence thinking regarding whether or not PARs are rational drug targets. Blockade of platelet activation by thrombin might well be a useful antithrombotic strategy. Attenuating inflammatory responses by blocking PAR signaling in endothelial cells is a more novel and untested notion, and impacting new blood vessel formation by the same route more speculative still. Results from mouse models may stimulate further exploration of these ideas.
